Guobao Zhao

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. Sign up for our updates here: https://bit.ly/HMBDNews

Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.

MicuRx Pharmaceuticals is a biotechnology company based out of Foster City, California USA and Shanghai, China.

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. Sign up for our updates here: https://bit.ly/HMBDNews

Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.

MicuRx Pharmaceuticals is a biotechnology company based out of Foster City, California USA and Shanghai, China.

Kunwu Jiuding Investment Holding Co., Ltd. (JD Capital), headquartered in Beijing, engaged in private equity investment management and real estate development and operation business. JD Capital is listed in Shanghai Stock Exchange listed (600053.SH). Kunwu Jiuding Investment Management Co., Ltd. is a wholly-owned subsidiary of JD Capital, a professional institution registered in Asset Management Association of China focusing on equity investment and management. The company is the co-chairman unit of equity and venture capital Professional Committee of Investment Association of China and the standing director unit of Zhongguancun Venture Capital and Equity Investment Fund Association. Explore further opportunities with us by visiting our careers page: Https://www.liepin.com/company/991663/